Compare DMRA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRA | ANAB |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2020 | 2015 |
| Metric | DMRA | ANAB |
|---|---|---|
| Price | $22.10 | $45.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $46.78 | ★ $87.25 |
| AVG Volume (30 Days) | ★ 478.7K | 368.2K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 121.48 | 91.02 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | $28.82 |
| Revenue Next Year | N/A | $24.35 |
| P/E Ratio | ★ N/A | $416.09 |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $16.50 | $33.10 |
| 52 Week High | $34.89 | $73.30 |
| Indicator | DMRA | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 39.87 |
| Support Level | $18.03 | $44.25 |
| Resistance Level | $22.27 | $57.55 |
| Average True Range (ATR) | 1.83 | 1.79 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 30.13 | 9.95 |
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).